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Innovations
Elixir Pharmaceuticals:
Targeting Molecular Sources of Aging
ton, Alli Puca, MD, a Kunkel post- organisms like bacteria all the way
up to man. “These targets play criti-doctoral fellow and prote´ge´, and
cal roles in cellular function in allThomas Perls, MD, MPH, the founder
Its name may initially provoke im-
ages promising the fountain—or
medicine—of youth. But the daily
business of Cambridge, MA-based species,” says DiStefano. The com-of the New England Centenarian
Elixir Pharmaceuticals could not be pany has taken that founding biol-Study, charged with collecting DNA
more current and high tech. Ac- ogy, looked at those pathways exist-samples from hundreds of 100-year-
cording to Peter DiStefano, PhD, ing in lower organisms, and askedold individuals.
Elixir’s Chief Scientific Officer, “The if they operate similarly in humans.Elixir had a model organism ge-
mission of the company is to identify “The short answer is that yes theynetics technology platform, whereas
the molecular targets involved in the do quite a bit, and they modulateCentagenetix had a human genetics
aging process and to manipulate cell division, the redox state of thetechnology platform it used to con-
those targets pharmacologically to cell, oxidative damage, apoptosis,duct genetic population association
prevent and treat a variety of age- and metabolic functions within thestudies. That was the core differ-
related diseases.” Elixir is a 30-per- cell,” says DiStefano. “And we’veence, although both companies were
son company of highly qualified sci- looked at various targets in thoseultimately pursuing drug discovery.
entists with serious reputations in pathways and started small mole-“It was the origins of the sources of
the fields of biology, genetics, aging, cule drug discovery programstargets and biochemical pathways
and longevity, focused on identi- around those targets.” The theory isthat were different,” says Watson.
fying key pathways involved in the that, gone awry, these pathwaysRepresentatives from both first-gen-
diseases usually associated with could give rise to many diseaseseration companies are on board at
aging. “But, we are not about creat- with increased prevalence in olderElixir, originally incorporated in
ing an anti-aging pill,” explains Alan people: cancer, cardiovascular dis-1999.
Watson, PhD, the company’s Chief ease, neurodegenerative disease,
Business Officer. “We are in the drug Alzheimer’s Disease, diabetes, and
discovery business, pursuing estab- other metabolic disorders. “These
“What is tantalizing aboutlished disease indications with dis- molecules or targets affect a lot of
these cellular processes that gocrete clinical endpoints.” the genetics is the inher-
An Evolved Partnership haywire in these diseases—that’sent pleiotropy it predicts“Elixir came into being focused on what’s really exciting,” adds Di-
across different diseasethe aging angle, and we now have a Stefano.
One of those pathways is thevery cogent disease-focused per- indications, potentially
spective,” says DiStefano. The com- DAF-2 pathway, partially drawn outtreatable with a singlepany’s initial technology platform by Dr. Kenyon in her study of C. ele-
small molecule.” –Alanwas contributed by its two scientific gans. “DAF-2 happens to be the or-
tholog of the IGF-1 receptor/insulinfounders, Cynthia Kenyon, PhD, Watson, PhD, Chief Busi-
from the University of California, San receptor in man,” explains DiStef-
ness Officer, ElixirFrancisco, and MIT’s Leonard Guar- ano. It is a highly conserved pathway
ente, PhD. Dr. Kenyon works mainly found in several organisms. Kenyon
in studies of C. elegans; Dr. Guar- discovered that altering a single nu-
Conventional, though Novel,ente studies yeast molecular genet- cleotide in the DAF-2 gene in the
Druggable Targetsics. These two researchers provided worm more than doubles its usual
“We are focusing on conventionalmuch of the model organism work life span. “The DAF-2 pathway has
druggable targets like cell surfacewherein important conserved path- a similar function in many different
receptors, enzymes, and the like,”ways involved in the diseases of species, and we have mined that
says DiStefano. But he acknowl-aging have been discovered and are pathway, looked for key intervention
edges he came to these from thenow being mined for pharmaceutical points in mammalian organisms,
early “aging platform” days at Elixir.targets at Elixir. In February 2003, identified targets, and mounted drug
“A lot of the model organisms workElixir merged with a sister company discovery programs around those
performed early on identified somein the world of aging studies, Centa- targets,” DiStefano says. In particu-
orthologous human targets in thesegenetix, Inc., also of Cambridge, lar, Elixir is interested in further in-
lower animals—worms, flies, andMA. The key drivers behind Centa- vestigating the recently discovered
yeast—as being critically involved ingenetix were Louis Kunkel, PhD, a association between diabetes and
controlling the aging process.” Itrenowned geneticist who is cur- neurodegeneration, such as that in
turns out that almost all those genes,rently director of the Genetics Pro- Alzheimer’s disease, in terms of the
DAF-2 insulin/diabetes pathway.gram at Children’s Hospital in Bos- pathways, and targets are found in
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“The other pathway we are work- of the Proceedings of the National development process,” according
to Watson. To take advantage of theing on came from Lenny Guarente’s Academy of Science. In addition,
Elixir continues a research collabo-yeast work involving the SIR2 path- clinical opportunities of this pleiot-
ropy, Elixir welcomes partnershipsway, or the ‘Silent Information Regu- ration with Dr. Francis Collins, direc-
tor of the National Human Genomelator’ pathway,” explains Watson. with pharmaceutical companies.
Says Watson, “This way we can“This is an entirely novel target in- Research Institute at the National In-
stitutes of Health, who is studyingvolved in a number of bioenergetic quickly get beyond the limitations of
a small company like ours to do theand potentially cancer-regulating the genetics of Hutchinson-Gilford
progeria syndrome, a disease of ac-pathways.” He further explains that breadth of clinical programs re-
quired to exploit what compoundsthere are seven human homologs of celerated aging. In May 2003, Dr.
Collins published results identifyingthe SIR2 gene in yeast, known as the like this could do for the treatment
of a range of age-related diseases.”SIR-T family. Adds DiStefano, “We the Lamin A gene as a central caus-
ative factor in progeria (Nature 423:have identified small molecule mod-
Chemistry & Biology invites yourulators of targets in both of these 293–298). “He is interested now in
comments on this topic. Pleasepathways and tested them in cell- comparing his Lamin A gene with
write to the editors at chembiol@based assays, and we have begun our centenarians as a gold standard
cell.com.looking at them in rodent-based control group,” according to Wat-
son. That collaboration will likelyin vivo models.” The company has Alice A. McCarthy is a freelance science
identified near lead-stage com- continue throughout the remainder writer based in Gloucester, MA (alice@
alicemccarthy.com).pounds in its DAF-2 program. “It is of this year.
Treatment, Not Preventiona medicinal chemistry approach
now to further identify those leads “We are focused on treatment:
things we can do to affect variousand come up with clinical candi-
dates,” says DiStefano. ongoing pathological processes in-
volved in a disease,” says DiStefano.Centenarian Genetics
Analysis Secondary The company has a big push in the
metabolic disease arena, pursuingCentagenetix contributed highly
publicized tantalizing work on a par- type II diabetes, obesity, and the
metabolic syndrome. “We are look-ticular area of human Chromosome
4. Researchers had identified a gene ing to see if modulation of these
pathways with our compounds willin that region as being critical to
longetivity: the MTTP (microsomal tip things in the right direction so
that we can alter lipid profiles or in-triglyceride transfer protein) gene.
“The good news was that it was sulin sensitivity and improve glu-
cose metabolism,” he says of a fewknown to be involved in triglyceride
regulation, something you would ex- key examples.
Elixir is firmly pathway drivenpect to be central with respect to
aging and longevity,” explains Wat- rather than therapeutic-area focused.
Instead of looking at longevityson. But the bad news for Centagen-
etix was that this known target had genes, as Centagenetix was, they
are searching for disease-basedbeen well trodden by about a dozen
large pharma companies and so was genes. “What is tantalizing about the
genetics is the inherent pleiotropynot an exclusive novel target. More
importantly, Centagenetix’s own cen- it predicts across different disease
indications, potentially treatabletenarian genetic association studies
showed that other genes aside from with a single small molecule,” says
Watson. “We are starting to seethose on Chromosome 4 must be
involved in the human longevity phe- glimmers of that in one of our pro-
grams, obesity and feeding disor-notype. “This is one of the reasons
we are not aggressively pursuing the ders, as a preliminary first indication.
You automatically begin looking atChromosome 4 findings,” says Wat-
son, even though Elixir recently re- a whole range of clinical chemistry
indicators including glucose levels,ceived a U.S. patent on the use of
the conserved area of Chromosome insulin levels, IGF-1, and growth hor-
mone levels.” He hopes that if the4 implicated in human longevity.
It should be noted that Kunkel and small molecule starts shifting pat-
terns in the right direction, theyPerls remain dedicated to the field
of identifying single-nucleotide poly- might have a compound with effi-
cacy not only in obesity but also formorphisms (SNPs)—bits of genome
sequences—and other longevity diabetes and possibly even neuro-
degeneration. “We can basicallygenes associated with aging. Kunkel
published a recent paper on the start to get to grips with that pleiot-
ropy advantage early on in the drugtopic in the November 25, 2003 issue
